Spyre Therapeutics Accelerates IBD Pipeline with Six Proof-of-Concept Readouts Expected in 2026
核心洞察
Spyre Therapeutics announced six expected proof-of-concept readouts in 2026 across its SKYLINE platform trial in ulcerative colitis (搜索) and SKYWAY basket trial in rheumatic diseases.
The company's SPY003 anti-IL-23 (搜索) antibody demonstrated well-tolerated safety profile with differentiated pharmacokinetics supporting quarterly or twice-yearly dosing in Phase 1 studies.
SKYLINE platform trial enrollment exceeded expectations with SPY001 enrollment completed ahead of schedule, accelerating Part A readouts to begin in Q2 2026.
Spyre Therapeutics is positioning itself for a transformational 2026 with six expected proof-of-concept readouts from its innovative platform trials targeting inflammatory bowel disease (搜索) and rheumatic conditions. The clinical-stage biotechnology company announced accelerated timelines for its SKYLINE platform trial in ulcerative colitis (搜索), with enrollment exceeding expectations and readouts now beginning in Q2 2026.
SKYLINE Platform Trial Shows Strong Momentum
The SKYLINE Phase 2 platform trial (NCT07012395) is evaluating SPY001 (anti-α4β7 (搜索)), SPY002 (anti-TL1A (搜索)), SPY003 (anti-IL-23 (搜索)), and pairwise combinations in patients with moderately to severely active ulcerative colitis (搜索). The trial consists of Part A, an open-label assessment of safety and preliminary efficacy of monotherapies, and Part B, a randomized placebo-controlled assessment of monotherapies and combinations.
"Enrollment in Part A has exceeded expectations with SPY001 enrollment completed ahead of schedule," the company reported. This acceleration has moved up the anticipated readouts, which are now expected to begin in Q2 2026 rather than the previously projected timeline.
SPY003 Demonstrates Differentiated Profile
At the 21st Congress of the European Crohn's and Colitis Organisation (ECCO), Spyre presented follow-up data from its Phase 1 study of SPY003 extending out to 20 weeks. According to Dr. Deanna Nguyen, SVP of Clinical Development at Spyre, "The data showed SPY003 was well tolerated, had a differentiated PK profile supporting quarterly or twice-yearly dosing, and demonstrated targeted biological activity via a reduction in downstream cytokines."
The interim Phase 1 results suggest potential for Q3M (quarterly) or Q6M (twice-yearly) maintenance dosing for inflammatory bowel disease (搜索), representing a significant advancement in dosing convenience for patients with chronic inflammatory conditions.
Combination Therapy Shows Superior Efficacy
Preclinical studies presented at ECCO demonstrated that dual targeting of TL1A (搜索) and IL-23 (搜索) can provide superior efficacy compared to either agent alone. The research, conducted in mouse anti-CD40 colitis models, showed that anti-TL1A and anti-IL-23 combination therapy was superior to its constituent monotherapies.
"These presentations highlight the strength of our antibody portfolio and our strategy to redefine the standard of care in IBD," said Dr. Nguyen.
SKYWAY Basket Trial Progresses Across Rheumatic Diseases
The SKYWAY Phase 2 basket trial (NCT07148414) is evaluating SPY072 (搜索) (anti-TL1A (搜索)) in patients with moderate to severely active rheumatoid arthritis (搜索), psoriatic arthritis (搜索), or axial spondyloarthritis (搜索). Enrollment remains on track across all three indications, with all readouts expected in Q4 2026.
Commercial Leadership Expansion
To support its advancing pipeline, Spyre appointed Kate Tansey Chevlen as Chief Commercial Officer. Ms. Tansey Chevlen brings nearly two decades of experience from Amgen, where she most recently served as VP, Global Marketing Head for Immunology and Inflammation.
"Spyre has one of the most compelling portfolios and development strategies in the autoimmune market, with multiple opportunities to deliver breakthrough medicines for patients in markets currently totaling more than $60B of annual revenue," said Ms. Tansey Chevlen.
Financial Position Supports Development Timeline
The company maintains a strong financial position with pro forma cash, cash equivalents, and marketable securities balance of $783 million as of September 30, 2025. This includes $486.2 million as of September 30, 2025, plus $296.5 million in net proceeds from an October 2025 underwritten public offering. The company anticipates this provides cash runway into the second half of 2028.
CEO Cameron Turtle emphasized the significance of the upcoming year: "Our six expected readouts this year have the potential to identify products, delivered as monotherapies or as combinations, that meaningfully improve upon the standard-of-care for patients suffering from IBD and rheumatic diseases."
The company's pipeline focuses on investigational extended half-life antibodies targeting α4β7 (搜索), TL1A (搜索), and IL-23 (搜索), with plans to initiate late-stage development in 2027 based on the proof-of-concept results expected throughout 2026.